The challenge of selecting the 'right' in vivo oncology pharmacology model.
The predictive value of non-clinical cancer pharmacology models has been poor with many drugs failing in the clinic that previously demonstrated anti-tumor responses in animal models. In the age of targeted drug discovery, the cancer pharmacologist is challenged with improving the translation of these models to a clinical setting. Various model systems currently utilized in preclinical cancer drug discovery are discussed and emphasis is placed on selecting models tailored to interrogate hypothesis-driven scientific questions.
Firestone
Brant
B
Oncology Pharmacology, Novartis Institutes for Biomedical Research, Inc., 250 Massachusetts Aveune, Cambridge, MA 02135, USA. brant.firestone@novartis.com
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D016867:Immunocompromised Host; D051379:Mice; D009362:Neoplasm Metastasis; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017154:Stromal Cells / Q000276:immunology / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
D000970:Antineoplastic Agents